| Summary of the segment profit or loss |
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
Nine months ended |
|
September 30, |
|
September 30, |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Revenue |
$ |
40,901 |
|
$ |
7,319 |
|
$ |
174,810 |
|
$ |
60,050 |
Less: |
|
|
|
|
|
|
|
|
|
|
|
Research |
|
(2,954) |
|
|
(4,197) |
|
|
(10,392) |
|
|
(9,570) |
CMC and Quality |
|
(15,073) |
|
|
(17,350) |
|
|
(44,006) |
|
|
(43,958) |
Biomarkers |
|
(1,196) |
|
|
(980) |
|
|
(6,482) |
|
|
(3,432) |
Development and Compliance |
|
(11,279) |
|
|
(13,128) |
|
|
(38,765) |
|
|
(32,165) |
Infrastructure management and Facilities |
|
(7,951) |
|
|
(7,491) |
|
|
(23,779) |
|
|
(20,981) |
Commercial |
|
(4,404) |
|
|
(550) |
|
|
(10,849) |
|
|
(1,976) |
Support functions |
|
(9,247) |
|
|
(8,643) |
|
|
(30,321) |
|
|
(37,278) |
Other segment expenses(a) |
|
(3,479) |
|
|
(1,613) |
|
|
(5,458) |
|
|
(575) |
Total operating expenses |
|
(55,581) |
|
|
(53,952) |
|
|
(170,051) |
|
|
(149,935) |
Operating (loss)/profit |
|
(14,680) |
|
|
(46,633) |
|
|
4,759 |
|
|
(89,885) |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
2,096 |
|
|
2,149 |
|
|
4,817 |
|
|
4,368 |
Interest expense |
|
(1,109) |
|
|
— |
|
|
(1,635) |
|
|
— |
Gain on bargain purchase |
|
— |
|
|
(106) |
|
|
— |
|
|
22,049 |
Other income (expense), net |
|
(3,093) |
|
|
(324) |
|
|
(2,657) |
|
|
(494) |
Income tax expense |
|
(831) |
|
|
(687) |
|
|
(1,883) |
|
|
(1,992) |
Segment and consolidated net (loss)/profit |
$ |
(17,617) |
|
$ |
(45,601) |
|
$ |
3,401 |
|
$ |
(65,954) |
(a)Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits, depreciation, amortization and share-based compensation expenses.
|